Molli Surgical (us) Inc
$30.6K 185 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
McKesson Drug Company LLC
McKesson Drug Company LLC reported $30,670.49 across General Payments, Research, and Ownership to 18 physicians and teaching hospitals across 18 transactions.
- $30.7K Below-median payer
- All-tracks total
- 18 Below-median volume
- Transactions
- 18 Below-median reach
- Recipients
- −$952.52
- General Payments vs PY2023
McKesson Drug Company LLC reported $30,670.49 across all CMS Open Payments tracks (General + Research + Ownership) to 18 physicians and teaching hospitals in Program Year 2024 - ranking #1465 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $30,670.49, averaging $1.7K per recipient.
McKesson Drug Company LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer mckesson-drug-company-llc McKesson Drug Company LLC
$30.7K · #1465/1,925 · 0.0% industry · PY2024
- TOT $30.7K
- RANK #1465
- SHARE 0.0%
- TXN 18
- RCP 18
- CAT 3
- GEN $30.7K
- ΔGEN −$952.52
- TOP1 65.2%
- PY 2024
Volume peers
Nearest volume peer: Molli Surgical (us) Inc ($30.6K)
McKesson Drug Company LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
McKesson Drug Company LLC's CMS-reported General Payments decreased by $952.52 (−3.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MCKESSON DRUG COMPANY LLCPY2023: MCKESSON DRUG COMPANY LLCPY2024: McKesson Drug Company LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $31,623.01
- PY2024
- $30,670.49
What the Data Shows for McKesson Drug Company LLC
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For McKesson Drug Company LLC that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Charitable Contribution" leads the 3-category general-payment breakdown below at $29.0K (94.6% of General Payments, 4 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 3 types of general payments, McKesson Drug Company LLC's largest category was "Charitable Contribution" at $29.0K - 94.6% of General Payments.
How McKesson Drug Company LLC divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Charitable Contribution | $29.0K | 4 | 94.6% |
| Food and Beverage | $1.3K | 13 | 4.1% |
| Honoraria | $407.00 | 1 | 1.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $29,407.00 (95.9%) of $30,670.49 in this company's General Payments records across 15 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for McKesson Drug Company LLC
The five named recipients with the highest reported General Payments from this company
- 1
Ochsner Clinic Foundation
$20,000.00 across 1 reported transactions
- 2
Yale-New Haven Hospital
$5,000.00 across 1 reported transactions
- 3
Kaleida Health
$2,500.00 across 1 reported transactions
- 4
Uams Medical Center
$1,500.00 across 1 reported transactions
- 5
Joseph Ezra Glaser
$407.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
McKesson Drug Company LLC ranks #1465 of 1,925 by total payments (bottom 24% by spend) but is notably more concentrated than that alone would suggest -- #397 of 1,838 by HHI (top 22% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.) : $72.2K total payments, HHI 4762
- EMD Millipore Corporation : $47.0K total payments, HHI 4713
- SunMed Group Holdings, LLC : $60.3K total payments, HHI 4712
- Techfit Digital Surgery Inc : $1.7K total payments, HHI 4709
- Advanced Sterilization Products Services Inc. : $76.1K total payments, HHI 4696
- Polymedco, LLC : $17.5K total payments, HHI 4621
- McKesson Drug Company LLC (this company) : $30.7K total payments, HHI 4613
- Ellex, Inc : $41.6K total payments, HHI 4605
- Haag-Streit USA, Inc. : $195.6K total payments, HHI 4605
- NeuraSignal Inc. : $8.3K total payments, HHI 4575
- Heru, Inc. : $11.0K total payments, HHI 4571
- Actuated Medical, Inc. : $8.0K total payments, HHI 4564
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as McKesson Drug Company LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about McKesson Drug Company LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with McKesson Drug Company LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
RIWOspine, Inc.
$30.8K 63 recipients
Compare payment profiles
Hubly Incorporated
$30.5K 4 recipients
Compare payment profiles
Intelivation Technologies, LLC
$30.3K 43 recipients
Compare payment profiles
Atlas Spine, Inc.
$31.3K 17 recipients
Compare payment profiles
Vitrolife Inc.
$31.3K 38 recipients
Compare payment profiles
Put this to use
McKesson Drug Company LLC ranks #1465 of 1,925 by all-tracks total payments, led by "Charitable Contribution".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Charitable Contribution" spend across every manufacturer, not just McKesson Drug Company LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.